Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650024 · ClinicalTrials.gov registry record
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
A clinical trial, sponsored by University of California, San Diego.
- Completed
- Registry status
- 16
- Enrollment target
NCT02650024 is a clinical trial that has completed, run by University of California, San Diego. The registered enrollment target is 16 participants.
The verdict
NCT02650024 has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV). The goals of this study are to determine the CNS impact of curing chronic HCV disease with newly established DAA therapies and how HIV alters this relationship.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650024
The ClinicalTrials.gov registry entry for NCT02650024 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02650024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02650024 about?
NCT02650024 is a clinical study titled "Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes". This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV). The goals of this study are to determine the CNS impact of curing chronic HCV disease with newly established DAA therapies an...
What is the current status of trial NCT02650024?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2016-01. Estimated completion is 2021-04.
Who is sponsoring clinical trial NCT02650024?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.